Further, the activation of RSKs and HIF-1α, in addition to Ras/MEK, may be useful as novel biomarkers in tumour biopsy samples to accurately predict the efficacy of 5-ALA-PDD and PDT in clinical settings. This evidence concerns the gene MAP2K7 and neoplasm.